Vaderis Therapeutics

Executive Summary

Vaderis Therapeutics is a Swiss biotech company founded in 2017, dedicated to developing breakthrough therapies for rare vascular diseases. Its lead focus is Hereditary Hemorrhagic Telangiectasia (HHT), a devastating genetic disorder characterized by abnormal blood vessel formation, leading to recurrent hemorrhages and complications. Currently, there are no approved therapies for HHT, representing a significant unmet medical need. Vaderis leverages a deep understanding of molecular pathways underlying vascular malformations to design small molecule therapies aimed at addressing the root cause of the disease. The company's patient-centric approach and robust preclinical data have positioned it for potential clinical advancement. With a strong scientific foundation and a clear target indication, Vaderis is poised to initiate clinical development in the near term. Upcoming milestones include regulatory designations and trial initiations that could validate its platform and drive value. While still early-stage, Vaderis represents a compelling opportunity in the rare disease space, with a focused strategy and a promising therapeutic candidate for a condition with high patient demand.

Upcoming Catalysts (preview)

• Q2 2026Orphan Drug Designation from FDA for HHT candidate90% success
• Q4 2026Initiation of Phase 1/2 clinical trial for lead candidate in HHT75% success
• Q3 2026Presentation of preclinical data at major medical conference95% success